NCIRE - The Veterans Health Research Institute Home  |  Sitemap  |  Intranet  |  UltiPro   Visit our Facebook page  Visit our Twitter page  Visit our LinkedIn page

Give Now
About NCIRE Participate in Research Support Our Mission Careers at NCIRE Contact Us
Veterans Health
Research at NCIRE

NCIRE-The Veterans Health Research Institute is the leading private nonprofit institute devoted to Veterans health research in the United States. Our mission is to advance Veterans health through research.

We support the work of some of the nation's foremost physicians and scientists at the San Francisco Veterans Affairs Medical Center, the premier biomedical research facility in the VA system. All have faculty appointments at the University of California, San Francisco, which has its own proud traditions of research and patient care. We also partner with the U.S. Department of Defense to support health research on behalf of our men and women in the Armed Forces.

Those who have served in uniform have given their best for their country. In return, we believe that they deserve nothing less than the best health care research we can provide.

Contact Us
Email NCIRE
Give Now
Peilin Li, MD

Assistant Professor, UCSF Research Scientist, SFVAHCS
Email: Peilin.li@ucsf.edu

Activation of latent HIV in CD4 T cells

Dr. Li's current research projects focus on activation of latent HIV in CD4 T cells and prevent HIV infection. HIV can establish a state of latency in individual T cells, and HIV is persistently produced in HIV patients, despite undetectable viral loads. The latent HIV reservoir is a major hurdle preventing the eradication and cure of HIV-1. Lifelong HAART is required, because the virus rebounds if HAART is stopped; however, prolonged HAART is costly and associated with various toxicities. Therefore, finding a way to eradicate latent HIV-1 has become an important goal. Dr. Li has found that Acitretin alone is a weak activator of HIV-1 transcription compare to suberoylanilide hydroxamic Acid (SAHA) (HDACi), or the phorbol ester, prostratin, but acts synergistically with SAHA or prostratin to greatly induce HIV expression from latently infected cells . Acitretin treatment increases RAR, RXR, IRF-1 and p300 expression but does not induce polyclonal activation of CD4 T cells as measured by gene expression and cell surface immunophenotyping for markers of T cell activation. Hope to define Acitretin as a new drug for use in combination treatment to reduce the latent HIV reservoir.

Dr. Li also studied  that exogenous HA can reduce infectivity of HIVCD44, but has no impact oninfectivity of HIVmock. Reduction of endogenous HA from CD4 T cells surface by hyaluronidase only enhances infectivity of HIVCD44. Exogenous HA decreasing of HIV infectivity is CD44 depended. Exogenous HA dwindled infectivity of HIVCD44 is involved lower phosphorylation of Protein Kinase C alpha (PKCa) via CD44. These results indicate that HA interaction with CD44 to modulate HIV infection through PKCa. HA is abundant in mucosal tissue, this finding may help to understand HIV transmission through mucosal tissue. This study may help to further understand HIV interaction with host factors in the mucosal tissue, to design potential novel approaches to prevent HIV infection through mucosal transmission.

To see Dr. Li on PubMed, click here.